Skip to main content

Advertisement

SpringerLink
Log in

Advanced renal cell carcinoma

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

For most patients with advanced renal cell carcinoma, treatment remains palliative. Standard chemotherapy used in the treatment of other types of cancers has proven ineffective in the treatment of this disease. High-dose interleukin-2 (IL-2) is the only regimen that has consistently shown benefit in advanced renal cell carcinoma. However, only a minority of patients is eligible for this treatment due to its toxicity, and only 15% to 20% of eligible patients respond with 7% long-term complete responses. Most investigational strategies in the treatment of advanced renal cell carcinoma are evaluating immunotherapeutic approaches, but participation of patients in clinical trials evaluating new novel cytotoxic agents or antiangiogenic agents remains an important option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Chow WH, Devesa S, Warren JL, et al.: Rising incidence of renal cell cancer in the United States. JAMA 1999, 281:17. Surveillance, Epidemiology, and End Results (SEER) database outlining the increasing incidence of renal cell carcinoma.

    Article  Google Scholar 

  2. Shuin T, Kondo K, Torigoe S, et al.: Frequent somatic mutations and loss of heterozygosity of the von Hippel- Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994, 54:2852–2855.

    PubMed  CAS  Google Scholar 

  3. Gnarra JR, Zhou S, Merrill MJ, et al.: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 1996, 93:10589–10594.

    Article  PubMed  CAS  Google Scholar 

  4. Gleave ME, Elhilali M, Mostafa F, et al.: Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998, 338:18. Good example of the variable natural history of advanced RCC.

    Article  Google Scholar 

  5. Oliver RTD, Nethersell ABW, Bottomley JM: Unexplained spontaneous regression and alpha interferon as treatment for metastatic renal carcinoma. Br J Urol 1989, 63:128–131.

    Article  PubMed  CAS  Google Scholar 

  6. Minasian LM, Motzer RJ, Gluck L: Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993, 11:1368–1375.

    PubMed  CAS  Google Scholar 

  7. Hyman M: Biologic Therapy of Cancer. JB Lippincott; 1991:298–311.

  8. Fisher RI, Rosenberg SA, Parkinson DR, et al.: Highdose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am 1997, 1:S70-S72. The current “standard” with the longest follow-up.

    Google Scholar 

  9. Negrier S, Escudier B, Lasset C, et al.: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998, 338:1272–1278.

    Article  PubMed  CAS  Google Scholar 

  10. Sparano JA, Fisher RI, Sunderland M, et al.: Randomized phase III trial of treatment with high-dose interleukin- 2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993, 11:1969–1977.

    PubMed  CAS  Google Scholar 

  11. Brewer GJ, Dick RD, Grover DK, et al.: Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase l study. Clin Cancer Res 2000, 6:1–10.

    PubMed  CAS  Google Scholar 

  12. Eisen T, Boshoff C, Sapunar F, et al.: Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000, 82:812–817.

    Article  PubMed  CAS  Google Scholar 

  13. Vissers JLM, DeVries JM, Schreurs MWJ, et al.: The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 1999, 59:5554–5559.

    PubMed  CAS  Google Scholar 

  14. Divgi CR, Bander NH, Scott AM, et al.: Phase I/II radioimmunotherapy trial with iodine-131 labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998, 4:2729–2739.

    PubMed  CAS  Google Scholar 

  15. Kugler A, Stuhler G, Walden P, et al.: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000, 6:332–336.

    Article  PubMed  CAS  Google Scholar 

  16. Chang AE, Aruga A, Cameron MJ, et al.: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997, 15:796–807.

    PubMed  CAS  Google Scholar 

  17. Childs RW: Nonmyeloablative allogeneic peripheral blood stem-cell transplantation as immunotherapy for malignant diseases. Cancer J 2000, 6:179–187. Novel approach to the immunotherapy of cancer.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Michigan Medical Center, 1500 East Medical Center Drive, 48109-7376, Ann Arbor, MI, USA

    Bruce G. Redman DO & Alfred E. Chang MD

Authors
  1. Bruce G. Redman DO
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alfred E. Chang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Redman, B.G., Chang, A.E. Advanced renal cell carcinoma. Curr. Treat. Options in Oncol. 1, 417–422 (2000). https://doi.org/10.1007/s11864-000-0069-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-000-0069-y

Keywords

Search

Navigation